ASCO: Biomarkers in Cancer Prevention

“Compared with pivotal trials, epcoritamab and glofitamab continue to be applied in a broad population of patients with high-risk large B-cell lymphoma,” said Taylor R. Brooks, MD.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

The primary end point of PFS was not statistically significant with sacituzumab govitecan vs chemotherapy as first-line treatment in HR+/HER2– metastatic breast cancer.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Giredestrant’s safety in the lidERA BC trial was consistent with its known profile, with a lower discontinuation rate vs SOC endocrine therapy.

Data from the phase 1b MonumenTAL-2 study support continued investigation of talquetamab/pomalidomide in the phase 3 MonumenTAL-6 trial.